India Share Brokers | Equity Trading India | Derivative Trading in India | Share Brokers in India

Markets Navigation

Company Info.

Remus Pharmaceuticals Ltd.

Income Statement - Standalone

Market Cap.(`)	1098.29 Cr.	P/BV	159.06	Book Value (`)	46.88
52 Week High/Low ( ` )	8747/1711	FV/ML	10/100	P/E(X)	129.17
Book Closure	02/05/2024	EPS (`)	57.72	Div Yield (%)	0.00

(` in Crs.)

You can view the Standalone Income Statement for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00


INCOME
Revenue From Operations [Net]	45.03	24.72	18.42	11.92
Total Operating Revenues	45.03	24.72	18.42	11.92

Other Income	1.58	0.72	0.81	0.85
Total Revenue	46.60	25.44	19.22	12.77

EXPENSES
Purchase Of Stock-In Trade	20.14	12.71	12.21	7.44
Changes In Inventories Of FG,WIP And Stock-In Trade	1.30	-0.44	-0.71	-0.40
Employee Benefit Expenses	5.47	3.49	3.00	2.86
Finance Costs	0.23	0.09	0.04	0.04
Depreciation And Amortisation Expenses	0.48	0.15	0.18	0.11
Other Expenses	7.57	4.89	3.17	1.63
Total Expenses	35.19	20.89	17.87	11.67

Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax	11.41	4.55	1.36	1.09

Profit/Loss Before Tax	11.41	4.55	1.36	1.09

Tax Expenses-Continued Operations
Current Tax	3.00	1.19	0.37	0.31
Deferred Tax	-0.09	-0.03	-0.03	-0.02
Total Tax Expenses	2.91	1.16	0.33	0.28
Profit/Loss After Tax And Before ExtraOrdinary Items	8.50	3.39	1.03	0.81

Profit/Loss From Continuing Operations	8.50	3.39	1.03	0.81

Profit/Loss For The Period	8.50	3.39	1.03	0.81

OTHER INFORMATION

EARNINGS PER SHARE
Basic EPS (Rs.)	83.24	33.86	10.26	8.12
Diluted EPS (Rs.)	83.24	33.86	10.26	8.12

DIVIDEND AND DIVIDEND PERCENTAGE
Equity Dividend Rate (%)	20.00	0.00	0.00	0.00

Remus Pharmaceuticals Ltd.

Balance Sheet - Standalone

Market Cap.(`)	1098.29 Cr.	P/BV	159.06	Book Value (`)	46.88
52 Week High/Low ( ` )	8747/1711	FV/ML	10/100	P/E(X)	129.17
Book Closure	02/05/2024	EPS (`)	57.72	Div Yield (%)	0.00

(` in Crs.)

You can view the Standalone Balance Sheet for the last 5 years.

Particulars	Mar 23	Mar 22	Mar 21	Mar 20
Months	12	12	12	12
Source Of Info (AR = Annual Report, PR = Press Release)	AR	AR	AR	AR
FaceValue	10.00	10.00	10.00	10.00
No. of Equity Shares (in Lacs)	10.85	10.00	0.10	0.10

EQUITIES AND LIABILITIES
SHAREHOLDER'S FUNDS
Equity Share Capital	1.09	1.00	0.01	0.01
Total Share Capital	1.09	1.00	0.01	0.01

Reserves and Surplus	18.05	5.43	3.04	2.01
Total Reserves and Surplus	18.05	5.43	3.04	2.01
Total Shareholders Funds	19.14	6.43	3.05	2.02

NON-CURRENT LIABILITIES
Long Term Borrowings	7.09	0.10	0.19	0.28
Long Term Provisions	0.28	0.18	0.12	0.08
Total Non-Current Liabilities	7.36	0.28	0.31	0.36

CURRENT LIABILITIES
Short Term Borrowings	0.85	0.09	0.09	0.08
Trade Payables	3.53	4.67	5.16	1.31
Other Current Liabilities	2.87	3.94	2.02	1.38
Short Term Provisions	0.91	0.49	0.42	0.16
Total Current Liabilities	8.16	9.20	7.69	2.93

Total Capital And Liabilities	34.66	15.91	11.05	5.30

ASSETS
NON-CURRENT ASSETS
Tangible Assets	2.49	0.31	0.39	0.50
Intangible Assets	0.05	0.00	0.00	0.00
Capital Work-In-Progress	0.02	0.00	0.00	0.00
Fixed Assets	2.56	0.31	0.39	0.50
Non-Current Investments	20.62	3.07	0.07	0.00
Deferred Tax Assets [Net]	0.13	0.09	0.06	0.03
Long Term Loans And Advances	0.00	4.74	3.03	0.00
Other Non-Current Assets	0.01	0.01	0.01	0.01
Total Non-Current Assets	23.32	8.22	3.55	0.54


CURRENT ASSETS
Inventories	0.29	1.59	1.15	0.44
Trade Receivables	4.85	2.92	3.60	1.63
Cash And Cash Equivalents	3.04	1.15	0.83	1.20
Short Term Loans And Advances	3.17	2.04	1.92	1.50
Total Current Assets	11.34	7.69	7.50	4.76

Total Assets	34.66	15.91	11.05	5.30

OTHER INFORMATION

CONTINGENT LIABILITIES, COMMITMENTS
Contingent Liabilities	94.36	0.00	0.00	0.00

BONUS DETAILS
Bonus Equity Share Capital	0.99	0.99	0.00	0.00

NON-CURRENT INVESTMENTS
Non-Current Investments Unquoted Book Value	20.62	3.07	0.00	0.00

Attention Investors : “Prevent unauthorized transactions in your account ? Update your Mobile Numbers/Email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your Mobile/Email at the end of the day. Issued in the interest of Investors” ***** No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. | | ***** KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. | "Revised guidelines on margin collection ==> 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. | 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | 3. Pay 20% upfront margin of the transaction value to trade in cash market segment. | 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. | 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors" | ***** MEMBERS : SEBI Regn. No: NSE, BSE: INZ000176636 ; MCX : INZ000057535; SEBI Research Analyst Regn No: INH200000337; AMFI Regn No. 77624; Depository Participant : CDSL : IN-DP-CDSL-379-2006 DP ID : 12047600 | For any Grievance mail to : grievance@sharewealthindia.com | For any DP Grievance mail to : dpgrievance@sharewealthindia.com. | Grievance with SEBI : https://scores.gov.in/scores/Welcome.html

Share Wealth

Remus Pharmaceuticals Ltd.

Income Statement - Standalone

Remus Pharmaceuticals Ltd.

Balance Sheet - Standalone